ANEB
Anebulo Pharmaceuticals, Inc.NASDAQHealthcare$0.75-24.24%ClosedMarket Cap: $30.6M
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
3.57
P/S
0.00
EV/EBITDA
-2.30
DCF Value
$0.34
FCF Yield
-20.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-74.6%
ROA
-84.7%
ROIC
-102.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $0.00 | NaN% | $-2.6M | $-2.0M | $-0.05 | — |
| Q1 2026 | $0.00 | NaN% | $-2.3M | $-2.2M | $-0.05 | — |
| Q4 2025 | $0.00 | NaN% | $-2.3M | $-2.1M | $-0.05 | — |
| FY 2025 | $0.00 | NaN% | $-9.2M | $-8.5M | $-0.25 | — |
| Q3 2025 | $0.00 | NaN% | $-1.9M | $-1.7M | $-0.06 | — |
| Q2 2025 | $0.00 | NaN% | $-2.6M | $-2.5M | $-0.09 | — |
| Q1 2025 | $0.00 | NaN% | $-2.4M | $-2.2M | $-0.08 | — |
| Q4 2024 | $0.00 | NaN% | $-1.3M | $-1.3M | $-0.05 | — |
| FY 2024 | $0.00 | NaN% | $-8.3M | $-8.2M | $-0.32 | — |
| Q3 2024 | $0.00 | NaN% | $-1.7M | $-1.7M | $-0.06 | — |
| Q2 2024 | $0.00 | NaN% | $-2.8M | $-2.7M | $-0.11 | — |
| Q1 2024 | $0.00 | NaN% | $-2.5M | $-2.5M | $-0.10 | — |